Venn Life Sciences Holdings


Clinical research organisation Venn Life Sciences Holdings plans to be a consolidator in the European clinical research market. Venn moved from ISDX to Aim following the reversal of the Venn business into Armscote in return for 9.6m shares at 30p each. A placing at 30p a share raised 2.5m (2.05m net) for the company, while shareholders who swapped their stake in the core business for shares in the quoted company raised 460,000. Venn was valued at 6m at the placing price.

Sector: Health

News blog

Browse by issue
All issues
Popular tags
All tags

betbrokers, financial, gold, health, leisure, media, mobile, resources, services, technology

AIM Micro feeds

Keep up to date with articles published at Subscribe to AIM Micro RSS Feeds